Page last updated: 2024-10-31

clorgyline and Androgen-Independent Prostatic Cancer

clorgyline has been researched along with Androgen-Independent Prostatic Cancer in 2 studies

Clorgyline: An antidepressive agent and monoamine oxidase inhibitor related to PARGYLINE.
clorgyline : An aromatic ether that is the 2,4-dichlorophenyl ether of 3-aminopropan-1-ol in which the nitrogen is substituted by a methyl group and a prop-1-yn-3-yl group. A monoamine oxidase inhibitor, it was formerly used as an antidepressant.

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (50.00)24.3611
2020's1 (50.00)2.80

Authors

AuthorsStudies
Wang, K1
Luo, J2
Yeh, S1
You, B1
Meng, J1
Chang, P1
Niu, Y1
Li, G1
Lu, C1
Zhu, Y1
Antonarakis, ES1
Huang, CP1
Xu, W1
Chang, C1
Gaur, S1
Gross, ME1
Liao, CP1
Qian, B1
Shih, JC1

Other Studies

2 other studies available for clorgyline and Androgen-Independent Prostatic Cancer

ArticleYear
The MAO inhibitors phenelzine and clorgyline revert enzalutamide resistance in castration resistant prostate cancer.
    Nature communications, 2020, 06-01, Volume: 11, Issue:1

    Topics: Alternative Splicing; Animals; Benzamides; Cell Line, Tumor; Cell Proliferation; Clorgyline; Drug Re

2020
Effect of Monoamine oxidase A (MAOA) inhibitors on androgen-sensitive and castration-resistant prostate cancer cells.
    The Prostate, 2019, Volume: 79, Issue:6

    Topics: Androgen Antagonists; Benzamides; Carcinogenesis; Cell Line, Tumor; Cell Proliferation; Clorgyline;

2019